Aurinia Pharmaceuticals Inc. AUPH R2KR3KPHARMA
Company Overview
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is headquartered in Edmonton, Canada.
Why Investors Should Care
Generates a return on equity of 66.1%, reflecting efficient use of shareholder capital.
Return on capital employed stands at 16.2%.
Revenue has grown at a 191.3% CAGR over the past five years.
Trades at a P/E of 7.0, below the sector median of 25.2.
Operating margin of 55.7% supports profitability.
Carries low leverage with a debt-to-equity ratio of 0.10.
Recent Developments
- Dec 2025 Revenue of $283.06M (+20.4% YoY); net profit $287.20M.
- Trailing 12 Months Year-on-year growth — revenue +18.9%, earnings +75.5%.
- 5-Year Trend Long-term compounding — revenue CAGR 191.3%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 191.33% |
| 1 Year: | 18.90% |
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | 75.50% |
Stock Price Performance
| 1 Year: | +33.89% |
| 6 Months: | +12.29% |
| 3 Months: | +1.52% |
| 1 Month: | -0.31% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)50.90 · Neutral
P/E of 7.05 is below the sector median of 25.17 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 66.1%.
- Compounding revenue at 191.3% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | AUPH Aurinia Pharmaceuticals Inc. R2KR3KPHARMA | 16.08 | 7.05 | $2.07B | 0.00% | 16.20% | 66.12% | 191.33% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 30.00K | 29.00K | 230.00K | 29.00K | 30.00K | 29.00K | 29.00K | 50.03M | 914.00K | 6.62M | 14.67M | 23.40M | 21.62M | 28.19M | 55.78M | 28.43M | 34.41M | 41.49M | 54.52M | 45.09M | 50.30M | 57.19M | - | - | 62.47M | 70.01M | 73.47M | 77.11M | 77.70M | 83.22M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 8.57M | 7.12M | 8.18M | 8.80M | 6.50M | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 53.89M | 62.89M | 65.29M | 68.31M | 71.20M | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 30.51M | 42.70M | 35.55M | 35.08M | 29.78M | - |
| Operating Income | -14.89M | -17.14M | -24.07M | -34.84M | -27.06M | -26.86M | -42.31M | -8.05M | -50.54M | -47.13M | -50.35M | -32.70M | -37.88M | -35.99M | -9.50M | -28.10M | -29.58M | -16.17M | -16.26M | -29.67M | -13.25M | -1.51M | - | - | 23.38M | 20.20M | 29.75M | 33.24M | 41.42M | 46.34M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 30.27M | 28.14M | 37.93M | 41.60M | 49.75M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.07M | 1.12M | 1.10M | 1.05M | 1.01M | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 24.35M | 22.16M | 31.96M | 35.69M | 43.92M | - |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.00M | 643.00K | 411.00K | -175.10M | 9.57M | - |
| Net Income | -14.10M | -16.38M | -23.45M | -34.46M | -25.93M | -26.54M | -42.13M | -8.07M | -50.38M | -47.01M | -50.26M | -33.32M | -37.63M | -35.52M | -8.99M | -26.05M | -26.21M | -11.49M | -13.45M | -26.88M | -10.75M | 722.00K | - | - | 23.34M | 21.51M | 31.55M | 210.79M | 34.35M | 37.41M |
| Diluted EPS | - | - | - | - | -0.23 | -0.24 | -0.34 | -0.06 | -0.40 | -0.37 | -0.39 | -0.25 | -0.27 | -0.25 | -0.06 | -0.18 | -0.18 | -0.08 | -0.09 | -0.19 | -0.07 | 0.01 | - | - | 0.16 | 0.16 | 0.23 | 1.53 | 0.25 | 0.28 |
| R&D Expense | - | - | - | - | 13.84M | 11.08M | 12.24M | - | 9.83M | 10.09M | 20.07M | - | 12.62M | 11.53M | 10.97M | - | 13.16M | 12.65M | 13.61M | - | 5.55M | 4.08M | 3.05M | - | 5.74M | 7.43M | 8.44M | - | 7.47M | 13.05M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 463.00K | 318.00K | 50.12M | - | 134.03M | 175.51M | 235.13M | 283.06M |
| Cost of Revenue | - | - | - | - | 5.66M | 14.15M | 28.25M | 32.66M |
| Gross Profit | - | - | - | - | 128.37M | 161.37M | 206.88M | 250.39M |
| Operating Expenses | - | - | - | - | 239.84M | 253.06M | 188.47M | 143.83M |
| Operating Income | -55.24M | -90.94M | -104.29M | - | -111.47M | -91.69M | 18.42M | 106.56M |
| EBITDA | - | - | - | - | -103.65M | -63.05M | 31.73M | 137.94M |
| Interest Expense | - | - | - | - | 0 | 2.77M | 4.83M | 4.33M |
| Pretax Income | - | - | - | - | -106.35M | -77.47M | 7.45M | 114.16M |
| Tax Provision | - | - | - | - | 1.83M | 551.00K | 1.70M | -173.04M |
| Net Income | -53.08M | -88.39M | -102.68M | - | -108.18M | -78.02M | 5.75M | 287.20M |
| Diluted EPS | - | -0.95 | -0.87 | - | -0.76 | -0.54 | 0.04 | 2.07 |
| R&D Expense | 41.38M | 52.87M | 50.33M | 51.14M | 44.99M | 49.64M | 20.79M | 32.51M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 324.30M | 463.66M | - | 470.86M | 548.06M | 550.64M | 751.59M |
| Current Assets | - | - | - | - | - | 442.54M | 424.80M | 446.60M | 491.97M |
| Cash & Equivalents | - | - | 306.02M | 272.35M | - | 94.17M | 48.88M | 83.43M | 80.21M |
| Inventory | - | - | - | - | - | 24.75M | 39.70M | 39.23M | 45.69M |
| Receivables | - | - | - | - | - | 13.48M | 24.09M | 36.54M | 41.45M |
| Total Liabilities | - | - | 25.70M | 55.91M | - | 65.42M | 170.11M | 173.17M | 170.26M |
| Current Liabilities | - | - | 11.29M | 32.00M | - | 46.11M | 77.19M | 97.76M | 93.72M |
| Long Term Debt | - | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | - | 8.09M | 97.61M | 79.37M | 74.81M |
| Total Equity | 177.92M | 135.72M | 298.60M | 407.75M | - | 405.44M | 377.95M | 377.48M | 581.33M |
| Shares Outstanding | - | - | - | - | - | 142.27M | 143.83M | 140.88M | 132.32M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -51.61M | -63.59M | -69.86M | - | -79.53M | -33.46M | 44.39M | 135.66M |
| Investing Cash Flow | -65.00K | 7.78M | -158.19M | - | -60.63M | -6.71M | 39.26M | -32.77M |
| Financing Cash Flow | 4.01M | 243.85M | 194.38M | - | 2.43M | -5.13M | -49.09M | -106.11M |
| Capital Expenditure | - | - | - | - | -292.00K | -718.00K | -281.00K | -252.00K |
| Free Cash Flow | - | - | - | - | -79.82M | -34.18M | 44.11M | 135.41M |
| Net Change in Cash | - | - | - | - | -137.73M | -45.30M | 34.56M | -3.22M |
| Share Buybacks | - | - | - | - | 0 | 0 | 40.24M | 98.16M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | 95.8% | 91.9% | 88.0% | 88.5% |
| Operating Margin % | -11,930.9% | -28,598.4% | -208.1% | - | -83.2% | -52.2% | 7.8% | 37.6% |
| Net Margin % | -11,464.1% | -27,794.0% | -204.9% | - | -80.7% | -44.5% | 2.4% | 101.5% |
| ROE % | -39.1% | -29.6% | -25.2% | - | -26.7% | -20.6% | 1.5% | 49.4% |
| ROCE % | - | -29.1% | -24.2% | - | -26.2% | -19.5% | 4.1% | 16.2% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Tang Capital Management, LLC | 9.80% | 13.04M | $212.49M |
| 2 | Blackrock Inc. | 6.16% | 8.19M | $133.47M |
| 3 | Goldman Sachs Group Inc | 4.22% | 5.62M | $91.54M |
| 4 | NEA Management Company, LLC | 2.98% | 3.97M | $64.67M |
| 5 | Two Sigma Investments, LP | 2.61% | 3.47M | $56.49M |
| 6 | Arrowstreet Capital, Limited Partnership | 2.45% | 3.26M | $53.17M |
| 7 | State Street Corporation | 1.95% | 2.59M | $42.18M |
| 8 | Morgan Stanley | 1.73% | 2.31M | $37.60M |
| 9 | Marshall Wace LLP | 1.54% | 2.04M | $33.30M |
| 10 | Geode Capital Management, LLC | 1.28% | 1.70M | $27.71M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for AUPH
Aurinia Pharmaceuticals (AUPH) Stock Still Looks Cheap After A 74% Gain - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxQZ3k2VzdPUU1wdWpTdllfVE1GRWZSM09uekpUQlpkOEs0YWNKNEdyXzRaYS0yMkxrMkVRTzZGT2RIbWpXZWhjcEE2eVRjNUdzc09fRzV4dkNvWHJCRnIwTXg0NlMwY1U4dEVFcHpwU281TVVwZDlCZTJyVkxSLWFNVEh6YXQ1Z3hXelpJMW…
AUPH Stock Sees Biggest Single-Day Drop In More Than 9 Months Despite Q1 Earnings Beat – Here’s What’s Spooking Investors - Stocktwits
<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxPSWViUnhseE1pRGhJaW5NMlNFUF80RHlsZjJVY25TQ083UW9rUUdVeGo1VC1vdVF5MVcxWTd2YThCaThVd1AzSmdOeHRodFNodC1OYVZkRDhjNnlSdnF1YUR6SDc5clMybGVYUS1qaC1sMF96S2NOaDZ0QkVxbmlTZmFwMUZlaUxjYVIxYV…
How Activist Investor Engagement At Aurinia Pharmaceuticals (AUPH) Has Changed Its Investment Story - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi7AFBVV95cUxQV3NzSVBwdnhhTG9LbjNUaHpnZUwyckxMTDAwaTJuQXh0UVdwOEdOTEZHdTZGVThMR2VUajlQRDY2WEdOT01BTGdoTTR3SDVRaDZoZzZ4V3lnOUg1cXd4SG9iLWFjczF3RXNtRXZvdi15eEIyU1dJc2RrajZyVkJTYzlzNXFvSW1BdHZhVk…
Responsive Playbooks and the AUPH Inflection - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxNZDlpWlBzVU5uclZIQTJxM1dGZC03QlNSRTY1cGdVVE82dDk0eE1KYVNsbFMzeXNDQk96d2hIX0hJNGFNc0p2NzU2V3BWMFFPYW5pTVRSaTBOb1JWcGVzRC1CV2poQWczQ09TT0Fsb3VKWG1kbEFGOC02cE9RQ094R1NOLUpiZklrYXctUl…
Aurinia's patents expire Dec. 2037, but Teva may launch a generic no earlier than Dec. 7, 2036 - Stock Titan
<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxQSHVqQ2UxUUxfbC1KQnotSU5Fd09JZW9GejIyUmU0OWcxczVQTTdGaU9XcmV6NU55SW13Znk4VVhGYXRSR0RGSWo3Z09oOWJkLTVRZVBoNzdxdE8tekVpWUtjdVJSeWM2RktmbWJSaDU0VURUSzlrREs2NkhPblFKN1JOc0lwTUllLUNBWW…
$AUPH stock is up 7% today. Here's what we see in our data. - quiverquant.com
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxNVWtXT2RWZDdfemc0NkFicHZtREFXOTVGTFo2RFNhSXlGeElvck1iTFVMQlJIemtfS3dUbjlLeG5IMEp6cVNVcHBPWWNIdVMxNmgtVnUwMHprTkJSYXl6M2RTUzRyaERLY3BJdUc2bzRmODhLeElwY0Q4TWQ2V0Q3WHEzaFE4YmJwbjhjX2…
AUPH — Frequently Asked Questions
What is the current share price of Aurinia Pharmaceuticals Inc. (AUPH)?
As of 2026-09-07 16:24 PDT, Aurinia Pharmaceuticals Inc. (AUPH) trades at $16.08 on NasdaqGM. Its 52-week range is $11.05 to $18.62.
What is the market capitalisation of AUPH?
Aurinia Pharmaceuticals Inc. (AUPH) has a market capitalisation of $2.07B on NasdaqGM.
What is the P/E ratio of AUPH?
AUPH trades at a trailing price-to-earnings (P/E) ratio of 7.05. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 3.65.
What is the return on equity (ROE) of AUPH?
AUPH has a return on equity (ROE) of 66.12%. Its return on capital employed (ROCE) is 16.20%.
Is AUPH a good stock to buy?
This page provides a data-driven analysis of Aurinia Pharmaceuticals Inc. (AUPH), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.